Should riluzole be used in patients with neurological disorders other than amyotrophic lateral sclerosis (ALS), and what are the appropriate dosing and liver function monitoring guidelines for ALS patients?

Riluzole Use in Neurological Disorders

Riluzole should only be used in patients with amyotrophic lateral sclerosis (ALS) and is not indicated for other neurological conditions. 1

FDA-Approved Indication

Riluzole is FDA-approved exclusively for the treatment of ALS 1. The evidence provided does not support its use in other neurological disorders such as restless legs syndrome, periodic limb movement disorder, or spinal cord injury, despite some investigational studies exploring off-label applications 2.

Dosing for ALS Patients

Standard dosing is 50 mg orally twice daily, taken at least 1 hour before or 2 hours after meals 1. This timing is critical as food intake affects drug absorption and bioavailability.

Key Dosing Evidence:

• The 100 mg/day dose (50 mg twice daily) demonstrated the best benefit-to-risk ratio in clinical trials 3, 4
• This dose extends survival by approximately 2-3 months compared to placebo 5
• Higher doses (200 mg/day) showed increased adverse effects without proportional benefit 3
• Lower doses (50 mg/day) showed less consistent efficacy 4

Liver Function Monitoring Protocol

Measure serum aminotransferases (ALT/AST) before initiating treatment, then monthly for the first 3 months, and periodically thereafter 1.

Specific Monitoring Guidelines:

Baseline Requirements:

• Do NOT initiate riluzole if baseline transaminases are >5 times upper limit of normal (ULN) 1
• Riluzole is contraindicated in patients with active liver disease 1

During Treatment:

• Monitor ALT/AST monthly for first 3 months 1
• Continue periodic monitoring after 3 months 1
• Approximately 50% of patients develop at least one elevated ALT above ULN 1
• About 8% develop ALT >3 times ULN 1
• 2% develop ALT >5 times ULN 1

Action Thresholds:

• Discontinue riluzole immediately if transaminases exceed 5 times ULN 1
• Discontinue if any evidence of liver dysfunction develops (e.g., elevated bilirubin) 1
• Maximum ALT increases typically occur within 3 months of starting treatment 1

Risk Factors for Hepatotoxicity:

Be particularly vigilant in patients with:

• Concurrent use of CYP1A2 inhibitors (doubles the risk of liver injury) 6
• History of smoking (increases risk by approximately 2-fold) 6
• Concurrent use of other hepatotoxic medications 1

Additional Safety Monitoring

Monitor for neutropenia, particularly in the first 2 months of treatment 1. Advise patients to report any febrile illness immediately, as severe neutropenia (absolute neutrophil count <500/mm³) has been reported 1.

Watch for interstitial lung disease or hypersensitivity pneumonitis 1. Discontinue riluzole immediately if these develop 1.

Clinical Efficacy Context

While riluzole modestly extends survival (median difference of 60-90 days in clinical trials) 1, 5, real-world studies suggest potentially greater benefit with survival extensions of 6-19 months 7. However, riluzole does not improve muscle strength or neurological function 1, 5—it only extends survival time.

Common Pitfalls to Avoid

• Do not crush tablets for patients with dysphagia—this causes drug loss and aspiration risk 7. Use oral suspension or oral film formulations instead
• Do not skip baseline liver function tests—this is the most critical safety measure
• Do not continue treatment if ALT exceeds 5× ULN—hepatotoxicity can be fatal 1
• Do not use in patients over 75 years or with very advanced disease without careful consideration, as efficacy data is limited in these populations 5

Contraindications

Riluzole is absolutely contraindicated in patients with:

• History of severe hypersensitivity reactions to riluzole (anaphylaxis has occurred) 1
• Baseline hepatic transaminases >5× ULN 1
• Active liver disease 1